-
Product Insights
Gonorrhea Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Gonorrhea is a sexually transmitted disease (STD) caused by the Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix, and endometrium, lining of the eyelid, the throat, and fallopian tubes. Symptoms include painful urination, pus-like discharge from the penis, increased vaginal discharge, abdominal pain, and pelvic pain. Treatment includes antibiotics. The Gonorrhea drugs in development market research report provide comprehensive information on the...
-
Product Insights
Otitis Media Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Otitis media (OM) is any inflammation of the middle ear, the air-filled space behind the eardrum that contains the tiny vibrating bones of the ear. Symptoms include ear pain, difficulty sleeping, loss of balance, fever, headache, and loss of appetite. Risk factors include age, seasonal factors, and exposure to tobacco smoke or high levels of air pollution. Treatment includes antibiotics and antipyrine. The otitis media drugs in development market research report provides an overview of the Otitis Media pipeline landscape....
-
Product Insights
Neisseria gonorrhoeae Infections – Global Clinical Trials Review, H2, 2020
GlobalData's clinical trial report, “Neisseria gonorrhoeae Infections - Global Clinical Trials Review, H2, 2020" provides an overview of Neisseria gonorrhoeae Infections Clinical trials scenario. This report provides top line data relating to the clinical trials on Neisseria gonorrhoeae Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type....
-
Product Insights
Mycoplasma pneumoniae Infections Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Mycoplasma pneumoniae Infections Global Clinical Trials Review, H1, 2018" provides an overview of Mycoplasma pneumoniae Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Mycoplasma pneumoniae Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Otitis Media Global Clinical Trials Review, H1, 2018
GlobalData's clinical trial report, “Otitis Media Global Clinical Trials Review, H1, 2018" provides an overview of Otitis Media clinical trials scenario. This report provides top line data relating to the clinical trials on Otitis Media. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Chlamydia Infections Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Chlamydia Infections Global Clinical Trials Review, H1, 2017" provides an overview of Chlamydia Infections clinical trials scenario. This report provides top line data relating to the clinical trials on Chlamydia Infections. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Community Acquired Pneumonia Global Clinical Trials Review, H1, 2017" provides an overview of Community Acquired Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community Acquired Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Community-Acquired Bacterial Pneumonia Global Clinical Trials Review, H1, 2017" provides an overview of Community-Acquired Bacterial Pneumonia clinical trials scenario. This report provides top line data relating to the clinical trials on Community-Acquired Bacterial Pneumonia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H1, 2017
GlobalData's clinical trial report, “Complicated Skin And Skin Structure Infections (cSSSI) Global Clinical Trials Review, H1, 2017" provides an overview of Complicated Skin And Skin Structure Infections (cSSSI) clinical trials scenario. This report provides top line data relating to the clinical trials on Complicated Skin And Skin Structure Infections (cSSSI). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...
-
Sector Analysis
Competitor Landscape: Non-alcoholic Steatohepatitis (NASH)
Sociable Pharma’s ‘Treatment Landscape’ contains evaluations of ongoing development activities within the NASH market, analysis of current & potential future product positioning, and forecast approval dates (by quarter) for candidates in Phase II development, or higher